Abstract Overview: Gilteritinib for FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia - 102164

Spotlight
Video

Abstract Overview: Gilteritinib for FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia

Loading........
Description: Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology gives an overview of an abstract presented by Jessica K. Altman, MD of Feinberg School of Medicine at Northwestern University, which focuses on gilteritinib for FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.

Abstract 7003: Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia
Shared By : AnnualMeeting2017
Posted on : 06/07/17
Added : 11 months ago